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ABSTRACT 
This study was performed to assess the short-term effect of sutureless scleral tunnel trabeculectomy procedure with and 
without topical bevacizumab. Thirty patients with Primary Open-Angle Glaucoma (POAG) were enrolled and randomly 
divided to two groups. Patients in the first group (15 patients) underwent sutureless trabeculectomy without topical 
bevacizumab and patients in the second group (15 patients) underwent sutureless trabeculectomy with 1.25 mg of 
topical bevacizumab. Intraocular Pressure (IOP) of both groups was measured by an expert ophthalmologist, without 
awareness of the patient’s study group before the operation and six months post-operatively. Out of 30 patients in this 
study, six females (40%) and nine males (60%) underwent the sutureless trabeculectomy procedure (group A) as well as 
seven females (46.7%) and eight males (53.3%) underwent sutureless trabeculectomy with topical bevacizumab (group 
B). The mean age of the patients was not significantly different between the two groups (P = 0.91). A statistically 
significant difference in time variation of IOP was found between the two groups (P < 0.001). Mean IOP was 18.4 ± 4.35 
mmHg in the sutureless group without bevacizumab and 11.73 ± 2.12 mmHg in the sutureless group with bevacizumab, 
six months post-surgically. No statistical significant differences were found in the baseline IOP between the two groups 
(P = 0.28). However, IOP changed significantly in group A and B from baseline to six months post-operatively (P = 0.004 
and P < 0.001 respectively). According to the current findings, the sutureless trabeculectomy procedure is an effective 
surgical method for reduction of IOP. Addition of a single dose of 1.25 mg topical bevacizumab was more effective in 
reduction of IOP compared to sutureless trabeculectomy alone. 
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INTRODUCTION
Trabeculectomy is the most important part of surgical 
management in Primary Open Angle Glaucoma (POAG) 
for the achievement of long term results [1-3]. In this 
filtering surgical technique, an ostium is created in the 
anterior chamber from underneath the partial thickness 
of the scleral flap, to help the aqueous outflow. When 
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the aqueous flows into the subconjunctival space, it 
usually leads to an elevation of the conjunctiva, referred 
to as a filtering bleb and this procedure can control Intra 
Ocular Pressure (IOP) [4]. Sutureless scleral tunnel 
trabeculectomy is an efficient surgical technique for 
reduction of IOP in patients with open angle glaucoma 
[5-7]. Antimetabolites are usually used during 
trabeculectomy surgery to prevent bleb failure due to 
scarring by the wound healing process. The most 
commonly used antimetabolites are 5-fluorouracil (5-FU) 
or Mitomycin C (MMC) [8-13], which can be applied and 
placed on the scleral surgical site before or after creation 
of a scleral flap and prior to creation of the ostomy. In 
the recent years, studies have reported greater efficiency 
and improvement of trabeculectomy outcomes, by using 
anti-angiogenesis factors, such as bevacizumab and 
ranibizumab [14, 15]. Due to controversies, which exist in 
the field of bleb formation and IOP reduction by 
bevacizumab application at the time of trabeculectomy, 
this study was performed to assess short-term results of 
sutureless scleral tunnel trabeculectomy procedure, 
using adjunctive topical bevacizumab, in comparison with 
sutureless scleral tunnel trabeculectomy without topical 
bevacizumab. 
MATERIALS and METHODS 
This study was conducted at AL Zahra Eye Hospital 
glaucoma department, a university-based hospital in 
Zahedan, Iran, between November 2015 and August 
2016. The study adhered to the declaration of Helsinki 
and was approved by the Ethics Committee of 
Ophthalmic Research Center affiliated to Zahedan 
University of Medical Sciences, Zahedan, Iran. Thirty 
phakic patients with POAG (13 females and 17 males) 
were selected for sutureless trabeculectomy and were 
randomly assigned to two groups using the random 
numbers table. The first group (A: 15 patients) received 
standard sutureless trabeculectomy, and the second 
group (B: 15 patients) received a standard sutureless 
trabeculectomy with topical bevacizumab. Inclusion 
criteria were having POAG and an IOP of > 21 mmHg, 
despite maximum tolerated medication and poor 
compliance. Exclusion criteria were: having history of 
ocular surgery, congenital glaucoma, ocular 
inflammation, angle closure glaucoma, secondary open 
angle glaucoma, and soft tissue disease (Marfan 
syndrome, collagen vascular diseases, etc.). Prior to the 
surgical procedure, all patients signed an informed 
consent and underwent detailed slit-lamp microscopy, 
gonioscopy, and dilated fundus examination. The IOP 
was measured by Goldman Applanation Tonometer 
(GAT) before the surgery by an expert ophthalmologist, 
without awareness of the patient’s study group. Also, all 
subjects were blind to the study conditions. Sutureless 
trabeculectomy was performed by one surgeon in both 
study groups. On the first postoperative day, all eyes 
were prescribed topical antibiotic (ciprofloxacin) and 
corticosteroid (betamethasone), three times daily for 
two weeks and the corticosteroid (betamethasone) was 
tapered over the following two months. All patients were 
fully evaluated at one and six months after the surgery 
and IOP was measured by GAT, six months after the 
surgery by an expert ophthalmologist, without 
awareness of the patient’s study group. Normal 
distribution of data was determined by the Kolmogorov 
Smirnov test. Independent t-test was used for evaluation 
of IOP between groups. Paired t-test was used for pre- 
and post-operative IOP changes in each group. For all 
tests, P < 0.05 was considered as statistically significant. 
Surgical Technique 
Sutureless trabeculectomy was performed under general 
anesthesia. After primary preparations, in superior 
limbus, the conjunctiva was opened in a fornix-based 
manner. The Tenon capsule was shaved and a bipolar 
cautery homeostasis was achieved. A tangential scleral 
tunnel was created 3 mm posterior to the superior 
limbus (width: 3 mm horizontally and depth: 
approximately one-third of the scleral thickness), using a 
crescent knife. This tunnel was progressed for 0.5 mm 
into the clear cornea, and anterior chamber was 
accessed using a 2.2-mm keratome.  
The anterior chamber was filled with methyl cellulose. 
The Kelly Descemet membrane punch (1.0 mm diameter 
head with 0.5 mm deep bite) was used to remove two 
punches of trabecular meshwork. After peripheral 
iridectomy, the methylcellulose was washed through the 
scleral tunnel incision, using an irrigation cannula and the 
anterior chamber was formed, using a balanced salt 
solution. Furthermore, 1.25 mg of topical bevacizumab 
(Roche Company, Basel, Switzerland) was placed on the 
scleral incision with a surgical sponge for one minute. 
The conjunctival flap was sutured with an 8-0 polyglactin 
suture (Vicryl; Ethicon Inc.). Subconjunctival 
betamethasone and cefazolin were injected and eyes 
were patched until the next day. Fig 1 shows a patient’s 
eye with avascular and elevated bleb after six months of 
sutureless trabeculectomy with topical bevacizumab 
attached. 
RESULTS 
Out of 30 patients participating in this study, six females 
(40%) and nine males (60%) underwent sutureless 
trabeculectomy (group A) as well as seven females 
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(46.7%) and eight males (53.3%) underwent sutureless 
trabeculectomy with topical bevacizumab (group B). The 
mean and standard deviation of age in group A was 52.4 
± 16.11 years and in group B was 51.80 ± 12.45 years. 
There were no statistical significant differences regarding 
gender (P = 0.71), eye laterality (P = 46.7%), and age (P = 
0.91) between the two groups. The IOP was checked at 
baseline and six months post surgically. The results 
showed a statistically significant change in IOP from the 
baseline to six months post-operatively (P = 0.004 and P 
< 0.001, respectively for group A and B) (Table 1). 
Paired sample T-test showed an IOP reduction in both 
groups, six months post-operatively. The baseline IOP 
was not significantly different between the two groups (P 
= 0.28). Six months post-surgically, mean IOP was 
18.4±4.35 mmHg in the sutureless group without 
bevacizumab and 11.73 ± 2.12 mmHg in the sutureless 
group with bevacizumab (Fig 2). 
 
 
Figure 1: Photograph of the Patient’s Eye with Avascular and Elevated 
Bleb Six Months after Sutureless Trabeculectomy with Topical 
Bevacizumab 
The results showed that six months post- operatively, IOP 
was significantly lower in group B as compared to the 
other group (P < 0.001). Time variation of IOP was also 
significantly different between the two groups (P = 
0.001). 
 
Table 1: The Mean Intra-Ocular Pressure (IOP) with and without Topical Bevacizumab 
 Group A Mean (SD) Group B Mean (SD) P (value) 
Baseline IOP 25.33 (8.82) mmHg 28.66 (7.74) mmHg 0.28 
IOP 6 months post- op 18.40 (4.35) mmHg 11.73 (2.12) mmHg < 0.0001* 
P- value 0.004* < 0.0001*  
Group A (Sutureless Trabeculectomy without Topical Bevacizumab) 
Group B (Sutureless Trabeculectomy with Topical Bevacizumab) 
IOP: intraocular pressure, SD: Standard Deviation, mmHg: millimeters of mercury,* = P-Values less than 0.05.  
 
 
Figure 2: Comparison of Baseline Intra Ocular Pressure (IOP) Six Months post Operatively between the two Groups: Group A (sutureless trabeculectomy 
without Topical Bevacizumab) and Group B (Sutureless  Trabeculectomy with Topical Bevacizumab). 
 
DISCUSSION 
This study evaluated the effect of sutureless scleral 
tunnel trabeculectomy in IOP reduction with and without 
topical bevacizumab. For this purpose, 15 patients 
underwent sutureless trabeculectomy with 1.25 mg 
topical bevacizumab. According to the findings, topical 
bevacizumab was very effective in IOP reduction in 
patients with POAG. Also, overall success rate of surgery 
in these patients was higher than the other group. Use of 
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Vascular Endothelial Growth Factor (VEGF) or Vascular 
Permeability Factor (VPF) is a method to increase the 
speed of wound and scars healing. Furthermore, VEGF 
can speed up angiogenesis by increasing common 
inflammatory cells, such as fibroblasts and other 
cytokines and growth factors, prior to wound healing [16, 
17]. Anti-VEGF drugs inhibit fibroblasts activity, which 
delays scar formation [18-21]. An animal trial showed 
that topical application of Bevacizumab on conjunctival 
tissue of rats has a direct effect on fibroblasts and 
inhibits expression of VEGF and Transforming Growth 
Factor beta (TGFb1, and TGFb2). These findings provide 
alternative mechanisms for Bevacizumab’s clinical 
application [22]. In some studies, the effect of 
intracameral injection of an anti VEGF and placebo had 
been compared in humans [23, 24]. This study confirms 
the results of previous studies regarding the efficacy of 
adjunctive anti-VEGF in reduction of IOP [14, 15, 24, 25]. 
Choi et al. [15], in a case series study, used 
subconjunctival injection of 1.25 mg bevacizumab at 
completion of trabeculectomy. Similar to the results of 
the current study, six months post-operatively, all eyes 
showed functioning blebs and IOP reduction. Fakhraei et 
al. [24], in a similar study, found a 30% drop in IOP after 
subconjunctival injection of 1.25 mg bevacizumab 
compared with base line values in patients with POAG 
and pseudoexfoliation glaucoma, yet they stated that 
this could increase the risk of early bleb leakage. Klos-
Rola et al. in 2013 assessed the effect of topical 
bevacizumab application on early bleb failure after 
trabeculectomy. Their results showed that in high risk 
eyes for bleb failure, post trabeculectomy, application of 
bevacizumab might favor functional bleb formation [25]. 
Kahook et al. investigated the effect of combination of 
intravitreal Ranibizumab and topical mitomycin c in bleb 
morphology and vascularity after trabeculectomy. Their 
results showed more diffuse blebs with less vascularity 
when using the combination of intravitreal Ranibizumab 
and topical mitomycin c at the time of trabeculectomy 
[26]. In the present study, topical Bevacizumab was 
chosen because of its lower complications and side 
effects [24]. 
On the other hand, there are reports in contrast to the 
current results that oppose the efficacy of adjunctive 
anti-VEGF [23]. Sadeghipour et al. used subconjunctival 
injection of 0.2 mg bevacizumab with augment 
trabeculectomy, on patients with POAG, and found no 
significant IOP reduction after six months. They 
concluded that the effect of bevacizumab injection on 
trend of IOP reduction was the same as the placebo [23]. 
The results of a research carried out by Suh et al. showed 
that  in their study, when bevacizumab was administered 
in combination with 5-FU, it did not have an additive 
effect in trabeculectomy [8]. Kaushik et al., in 2017, 
compared the efficacy of bevacizumab- and mitomycin c-
modulated trabeculectomy in POAG. They found that 
adjunctive bevacizumab was comparable with MMC in 
reducing IOP for the first year [27]. According to the 
current findings, topical bevacizumab application is safe 
and has a significant effect in IOP reduction. In this study 
topical bevacizumab was used alone without adding any 
other anti-fibrotic and anti-metabolite agents. The 
current study had some limitations, including the short 
time follow up and the number of the cases. Studies with 
greater number of patients and longer duration of follow 
up should be designed to establish more significant long 
term results.  
CONCLUSION 
sutureless scleral tunnel trabeculectomy is an effective 
procedure for reduction of IOP yet a single dose of 1.25 
mg of topical bevacizumab is significantly more effective 
in reducing IOP, as compared to the sutureless 
trabeculectomy alone. 
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